Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)
Status:
Recruiting
Trial end date:
2023-12-02
Target enrollment:
Participant gender:
Summary
The study aims at optimizing extended management of elderly patients (> 75 years) with at
least one of the known bleeding risk factor, who suffered from first episode of venous
thromboembolism of the lower extremity (proximal deep vein thrombosis with or without
pulmonary embolism) (VTE). Patients were randomized to receive three different treatment:
Sulodexide 250 mg BIS in die; Sulodexide 500 BID in die or indistinguishable placebo to
verify the efficacy and safety of extended treatment for 12 months with Sulodexide (Vessel®)
in the secondary prevention of Deep Vein Thrombosis / Pulmonary Embolism (DVT/PE) recurrence.